1,030.00
+0.19%
Close of 9 Nov 2026, in ILA
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Rekah Pharmaceutical Industry
Its shares trade on Tel Aviv under the ticker REKA.TA. It has been listed since 14 December 1995. In the fiscal year to 31 December 2024, it reported revenue of ILS 321.7m and net income of ILS 6.2m. At that date it held total assets of ILS 447.2m and shareholders' equity of ILS 161.9m.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 14 Dec 1995
- Employees
- 434
- Website
- rekah.co.il ↗
Leadership
Pay as last reported
- Mr. Avraham BigerChairman of the Board, since 2015
- Mr. Arye ElgrablyChief Executive Officer, Director, since 1993ILS 1.5m
- Mr. Yuval ElgrablyDeputy Chief Executive Officer
- Haim CohenChief Financial Officer
- Mr. Yuval BernshteinVice President - Finance
- Mr. Menachem DasbergVice President-Economic Division Manager, since 2014
- Ms. Georgette ElgrablyHead of Industrial Division, Director, since 1993ILS 1.4m
- Ronit ZelnikHead of Projects Division
- Mr. Amiram BoehmDirector
- Mr. Ishay DavidiDirector
- Prof. Ehood NisanExternal Director
- Ms. Orly ZilbermanExternal Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Rekah Pharmaceutical Industry Ltd. operates two GMP-approved manufacturing sites in Holon, Israel.
- Rekah's plant covers 5,000 square meters with advanced automated packaging techniques.
- Rekah distributes products through Ophir & Shalpharm to institutional users like hospitals and health funds.
Weaknesses
- Rekah has a marketing and distribution arm but lacks a strong online presence.
- Rekah's subsidiaries include Vitamed and CenterPharm but do not cover all product segments.
- Rekah's sterile department meets FDA standards but has limited export capabilities.
Opportunities
- Rekah can expand its export import unit to new markets in Europe and Asia.
- Rekah's vitamins and nutritional supplements segment shows growth potential in Israel.
- Rekah's pharmacy chain can increase market share in the Israeli retail sector.
Threats
- Rekah faces competition from other generic drug manufacturers in Israel.
- Rekah's reliance on institutional sales to Israel Health Funds poses a risk.
- Rekah's manufacturing sites may face regulatory challenges in the Health Care sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.